29 Results for "

TREK inhibitors

" in MedChemExpress (MCE) Product Catalog:
Products (29)

29 Results for "TREK inhibitors" in MCE Product Catalog:

12
12 Publications Verification
Cat. No.: HY-103371
CAS No.: 82749-70-0
Purity:  99.83%
Research Areas:  

Neurological Disease

DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0563
CAS No.: 84057-95-4
Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0563B
CAS No.: 98717-15-8
Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0563A
CAS No.: 132112-35-7
Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0563C
CAS No.: 854056-07-8
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane .
loading...
    loading...
Cat. No.: HY-P3581
CAS No.: 1801959-12-5
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

PE 22-28 is a TREK-1 inhibitor with IC50 value of 0.12 nM. PE 22-28 also is a 7 amino-acid peptide that is used as a core sequence for preparing analogs by chemical modifications and also by substitution of amino-acids. PE 22-28 can be used for the research of depression .
loading...
    loading...
Cat. No.: HY-W011235
CAS No.: 57226-68-3
Norfluoxetine hydrochloride is the active metabolite of the antidepressant Fluoxetine (HY-B0102); it is also a TREK-2 K2P potassium channel inhibitor. Norfluoxetine hydrochloride exhibits neuroimmunological activity, induces apoptosis in primary microglial cells, and inhibits the release of pro-inflammatory factors. Norfluoxetine hydrochloride inhibits high-threshold voltage-gated Ca 2+ currents in neurons with an EC50 of 20.4 μM. Norfluoxetine hydrochloride can be used in research related to depression, ischemic stroke, and epilepsy .
loading...
    loading...
Cat. No.: HY-B0563S1
CAS No.: 684647-62-9
Ropivacaine-d7 is deuterium labeled Ropivacaine. Ropivacain is a potent?sodium channel?blocker. Ropivacain blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain?management .
loading...
    loading...
Cat. No.: HY-137563
CAS No.: 88349-90-0
Purity:  98.50%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

A2793 is an efficient dual TWIK-related acid-sensitive K + channel (TASK)-1/TRESK inhibitor, with an IC50 of 6.8 μM for mTRESK. A2764 is more selective for TRESK, and it only moderately influences TREK-1 and TALK-1 .
loading...
    loading...
Cat. No.: HY-135556
CAS No.: 83891-03-6
Norfluoxetine is the active metabolite of the antidepressant Fluoxetine (HY-B0102); it is also a TREK-2 K2P potassium channel inhibitor. Norfluoxetine exhibits neuroimmunological activity, induces apoptosis in primary microglial cells, and inhibits the release of pro-inflammatory factors. Norfluoxetine inhibits high-threshold voltage-gated Ca 2+ currents in neurons with an EC50 of 20.4 μM. Norfluoxetine can be used in research related to depression, ischemic stroke, and epilepsy .
loading...
    loading...
Cat. No.: HY-135809
CAS No.: 861038-72-4
Purity:  99.05%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

A2764 dihydrochloride is a highly selective inhibitor of TRESK (TWIK-related spinal cord K + channel, K2P18.1), which has moderate inhibitory effects on TREK-1 and TALK-1. A2764 dihydrochloride is more sensitive to the activated mTRESK channels (IC50=6.8 μM) than the basal current. A2764 dihydrochloride can lead to cell depolarization and increased excitability in native cells, it has the potential for probing the role of TRESK channel in migraine and nociception .
loading...
    loading...
Cat. No.: HY-179004
CAS No.: 2640753-22-4
Synonyms: VU6022856
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ONO-9517601 is a potent, orally active, selective and CNS penetrant dual TREK-1/TREK-2 inhibitor (TREK-1 IC50= 0.067 μM, TREK-2 IC50= 0.23 μM). ONO-9517601 displays robust efficacy in an MK-801 (HY-15084B) challenge rat novel object recognition (NOR) paradigm. ONO-9517601 can be used for research on neurological and cognitive disorders .
loading...
    loading...
Cat. No.: HY-W011235S
CAS No.: 1188265-34-0
Norfluoxetine-d5 hydrochloride is the d5-labeled Norfluoxetine hydrochloride (HY-W011235). Norfluoxetine hydrochloride is the active metabolite of the antidepressant Fluoxetine (HY-B0102); it is also a TREK-2 K2P potassium channel inhibitor. Norfluoxetine hydrochloride exhibits neuroimmunological activity, induces apoptosis in primary microglial cells, and inhibits the release of pro-inflammatory factors. Norfluoxetine hydrochloride inhibits high-threshold voltage-gated Ca 2+ currents in neurons with an EC50 of 20.4 μM. Norfluoxetine hydrochloride can be used in research related to depression, ischemic stroke, and epilepsy .
loading...
    loading...
Cat. No.: HY-179005
CAS No.: 2640753-27-9
Synonyms: VU6024391
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ONO-7927846 is a potent, orally active, selective and CNS penetrant dual TREK-1/TREK-2 inhibitor (TREK-1 IC50= 0.11 μM, TREK-2 IC50= 0.29 μM). ONO-7927846 displays robust efficacy in an MK-801 (HY-15084B) challenge rat novel object recognition (NOR) paradigm. ONO-7927846 can be used for research on neurological and cognitive disorders .
loading...
    loading...
Cat. No.: HY-134559
CAS No.: 326921-25-9
Purity:  99.73%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

TKIM is a TREK-1 channel inhibitor with an IC50 of 2.96 μM. TKIM binds to the pocket of the intermediate (IM) state of TREK-1 .
loading...
    loading...
Cat. No.: HY-135556AS
CAS No.: 1185132-92-6
Norfluoxetine-d5 is the d5-labeled Norfluoxetine (HY-135556). Norfluoxetine is the active metabolite of the antidepressant Fluoxetine (HY-B0102); it is also a TREK-2 K2P potassium channel inhibitor. Norfluoxetine exhibits neuroimmunological activity, induces apoptosis in primary microglial cells, and inhibits the release of pro-inflammatory factors. Norfluoxetine inhibits high-threshold voltage-gated Ca 2+ currents in neurons with an EC50 of 20.4 μM. Norfluoxetine can be used in research related to depression, ischemic stroke, and epilepsy .
loading...
    loading...
Cat. No.: HY-149537
CAS No.: 1440532-32-0
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

TWIK-1/TREK-1-IN-2 (Compound 2g) is a TWIK-1/TREK-1 inhibitor. TWIK-1/TREK-1-IN-2 inhibits TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 10.13 μM and 15.5 μM. TWIK-1/TREK-1-IN-2 is an antidepressant .
loading...
    loading...
Cat. No.: HY-149536
CAS No.: 1440532-30-8
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects .
loading...
    loading...
Cat. No.: HY-149538
CAS No.: 1440532-33-1
Purity:  99.61%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects .
loading...
    loading...
Cat. No.: HY-116704
CAS No.: 37786-06-4
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

11-Deoxyprostaglandin F2α is an activator for TREK-2 channels with EC50 of 0.294 μM. 11-Deoxyprostaglandin F2α inhibits the K2P channel TREK-1 .
loading...
    loading...